<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">It is thought that dampening the hyperinflammatory reaction outweighs the risk of temporary impairment in antiviral immunity. Numerous clinical trials are underway to examine the therapeutic potential of various immunosuppressive and immunomodulatory agents in the treatment of COVID-19 and the potential associated cytokine storm. Existing drug safety data and relevant trial data are presented below.</p>
